Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyCapital Bluecross Diabetic Testing Prior Auth | Op…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy N/A

    Diabetic Testing Supplies Prior Authorization Criteria Medicare Part B

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Capital Blue Cross Medicare Part B prior authorization requirements for diabetic testing supplies (test strips, lancets, meters) and identifies preferred vs nonpreferred products; applies to providers and Medicare Part B members.

    Policy Summary
    PayerCapital Bluecross
    PolicyDiabetic Testing Supplies Prior Authorization Criteria Medicare Part B
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2025
    Next Review DateSep 1, 2025
    Key ActionPrior authorization is required for nonpreferred diabetic testing supplies; prescribers must try one preferred Ascensia product and document failure or limitation before a nonpreferred product will be approved.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare Part Bprogram applicability

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2026
    year
    Onepreferred trial
    All testing suppliestarget agents
    Pogo addedadmin note

    Coverage Criteria

    Prior Authorization Approval Criteria

    Evaluation: Diabetic testing supply target(s) will be approved when BOTH of the following are met:

    Overall approval logic: Both criteria 1 AND 2 must be satisfied for approval
    Criterion 1: One of the following: (a) Information has been provided that the patient has been treated with a diabetes medication within the past 90 days; OR (b) Information has been provided that the patient has been treated with a concomitant drug that may affect blood sugar levels within the past 90 days; OR (c) The patient has gestational diabetes; OR (d) The patient is prediabetic or diabetic90 days for medication/concomitant drug
    Criterion 2: The prescriber has provided information indicating the patient has failed or has limitations precluding use of the preferred diabetic testing supply product(s) (as determined by client)

    Client-determined preferred products list applies

    Continuous glucose monitoring devices are explicitly excluded from this prior authorization program. The program applies to diabetic testing supplies such as test strips, lancets, and meters, but continuous blood glucose monitors (CGMs) are not included in the program.

    Coding — Preferred and Nonpreferred Products

    Preferred Diabetic Testing Supply GPIsmixedCovered
    GPI=94100030006100Contour/Contour Next Test Strips
    GPI=97202010006200Contour Blood Glucose Monitoring System
    GPI=97202010006400Contour Next One Blood Glucose Monitoring System
    GPI=97202010006410Contour/Contour Next Blood Glucose Monitoring Systems
    Nonpreferred Diabetic Testing Supply GPIsmixedNot Covered
    GPI=94100030006100Blood Glucose Test Strips
    GPI=94100030006020Test cartridges
    GPI=97202010006200Blood Glucose Monitoring Device
    GPI=97202010006400Blood Glucose Monitoring Kit
    GPI=97202010006410Blood Glucose Monitoring Kit

    Provider Actions and Prior Authorization Workflow

    Prior Authorization

    Prior Authorization Required for Nonpreferred Products

    Prior authorization is required for nonpreferred diabetic testing supplies. One preferred Ascensia product (e.g., Contour/Contour Next test strips or system) must be tried and documented by the prescriber before a nonpreferred product will be authorized.

    • Preferred products: Ascensia/Contour/Contour Next (GPI examples: 94100030006100; system GPIs: 97202010006200, 97202010006400, 97202010006410).
    • Nonpreferred products: non-Ascensia blood glucose test strips, cartridges, devices, and kits (see GPI ranges in source).
    • OneTouch products: covered at 20% coinsurance and do not require PA.
    Step Therapy

    Preferred-product Trial Required

    Step requirement: the prescriber must document a trial of ONE preferred Ascensia product prior to requesting authorization for a nonpreferred diabetic testing supply. Documentation should specify which Ascensia product was used and the clinical rationale for switching to a nonpreferred product.

    Definitions

    Diabetic testing supplies — definitions for strips, meters, lancets, and CGM exclusion
    Blood glucose test stripsTest strips intended for quantitative self-monitoring of blood glucose (SMBG) by people with diabetes; used with compatible meters to measure glucose in blood samples outside the body.
    Blood glucose meters (BGM)Portable glucose meters used with test strips to quantitatively measure glucose for SMBG by people with diabetes and in clinical settings.
    LancetsSmall, single-use devices used to obtain capillary blood samples for SMBG when used with test strips and meters.
    Continuous glucose monitors (CGMs)Continuous glucose monitors are explicitly excluded from this program and are not covered as part of this diabetic testing supplies policy.
    Intended useStrips, lancets, and meters are intended for use outside the body for self-monitoring of blood glucose (SMBG) at home and by healthcare professionals in clinical settings to aid monitoring of diabetes control.

    Background

    Blood glucose test strips, lancets, and meters are used for quantitative self‑monitoring of blood glucose by people with diabetes and in clinical settings. This program covers those diabetic testing supplies for Medicare Part B members and defines prior authorization requirements for nonpreferred products; it does not apply to continuous glucose monitoring systems.

    Policy Summary
    PayerCapital Bluecross
    PolicyDiabetic Testing Supplies Prior Authorization Criteria Medicare Part B
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2025
    Next Review DateSep 1, 2025
    Key ActionPrior authorization is required for nonpreferred diabetic testing supplies; prescribers must try one preferred Ascensia product and document failure or limitation before a nonpreferred product will be approved.
    SourceLink
    On This Page
    Coverage CriteriaCoding — Preferred and Nonpreferred ProductsProvider Actions and Prior Authorization WorkflowDefinitionsBackground
    • Prescriber must provide evidence of trial of ONE preferred Ascensia product (e.g., Contour/Contour Next strips or system).
    • If the patient could not use the preferred product, the prescriber must describe the limitation or failure that precludes its use.
    Documentation Required

    Documentation Required from Prescriber

    Provider must supply evidence that the patient meets the authorization clinical trigger and that the preferred-product trial requirement is met. Acceptable documentation includes medication history showing treatment with a diabetes medication or a concomitant drug affecting blood sugar within the past 90 days, or documentation of gestational diabetes, prediabetes, or diabetes.

    • Clinical trigger: treatment with a diabetes medication within the past 90 days, OR treatment with a concomitant drug that may affect blood sugar within the past 90 days, OR diagnosis of gestational diabetes, prediabetes, or diabetes.
    • Documentation of the preferred Ascensia product trial and clinical reason for failure/limitation of the preferred product.
    Denial Risk

    Denial Triggers for Prior Authorization

    Requests for nonpreferred diabetic testing supplies may be denied if BOTH the clinical trigger (see documentation requirements) and the preferred-product trial (ONE preferred Ascensia product) are not met or not adequately documented.

    • Denial may occur when clinical evidence of diabetes treatment or qualifying diagnosis within the past 90 days is absent.
    • Denial may occur when prescriber fails to document trial of ONE preferred Ascensia product or adequate rationale why preferred product cannot be used.